Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N57CAR-T
- Development stage
- Unknown
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
N57CAR-T is a second-generation, murine-based chimeric antigen receptor (CAR) T-cell therapy designed to target the CD7 antigen. It incorporates 4-1BB and CD3ζ co-stimulatory domains to enhance T-cell activation and persistence. A novel "naturally selected" approach is utilized in its generation to overcome CD7-directed fratricide without requiring gene editing. This therapy is being evaluated for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), particularly in patients with central nervous system (CNS) involvement.
- Other names
- NS7CAR-TNS-7CAR-TNS 7CAR-T
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on N57CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N57CAR-T.